Comparison of survival and adverse events between women with stage IB1 and stage IB2 cervical cancer treated by laparoscopic radical vaginal hysterectomy

Jin-Hwa Hong, Joong Sub Choi, Jung Hun Lee, Chang Eop Son, Seung Wook Jeon, Jong Woon Bae, Jeong Min Eom

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Purpose: The goal of this study was to evaluate the operative feasibility and survival for patients with stage IB2 cervical cancer who undergo laparoscopic radical vaginal hysterectomy (LRVH) compared with those with stage IB1 cervical cancer. Methods: We identified 90 patients who were eligible to participate in the study through retrospective analysis of medical records from March 2003 to June 2010. Patients with stage IB1 cervical cancer were divided into two groups by a cutoff value of 2 cm for tumor size. Data regarding surgicopathologic risk factors, surgical outcomes, and survival rates were compared among three groups (two with stage IB1 and one with stage IB2). Results: The tumor size was ≤2 cm in 27 patients, 2-4 cm in 30, and >4 cm in 33. The number of intermediate and high-risk factors was significantly lower in patients with stage IB1 cervical cancer (≤2 cm) than in those with stage IB2. Surgical outcomes (mean operating time, estimated blood loss, number of harvested lymph nodes, and sites of metastatic lymph nodes) did not show any significant difference among the three groups. The rates of intraoperative complications also did not differ among the three groups (P = 0.833). The estimated 5-year recurrence-free and overall survival rates were not significantly different among the three groups (P = 0.253 and 0.525, respectively). Conclusions: LRVH for stage IB2 cervical cancer can be performed with similar safety and survival rates compared to stage IB1 cervical cancer. Overall, LRVH is feasible for the treatment of stage IB2 cervical cancer.

Original languageEnglish
Pages (from-to)605-611
Number of pages7
JournalAnnals of Surgical Oncology
Volume19
Issue number2
DOIs
Publication statusPublished - 2012 Feb 1
Externally publishedYes

Fingerprint

Vaginal Hysterectomy
Uterine Cervical Neoplasms
Survival
Survival Rate
Lymph Nodes
Intraoperative Complications
Medical Records
Neoplasms
Retrospective Studies
Safety
Recurrence

ASJC Scopus subject areas

  • Surgery
  • Oncology

Cite this

Comparison of survival and adverse events between women with stage IB1 and stage IB2 cervical cancer treated by laparoscopic radical vaginal hysterectomy. / Hong, Jin-Hwa; Choi, Joong Sub; Lee, Jung Hun; Son, Chang Eop; Jeon, Seung Wook; Bae, Jong Woon; Eom, Jeong Min.

In: Annals of Surgical Oncology, Vol. 19, No. 2, 01.02.2012, p. 605-611.

Research output: Contribution to journalArticle

Hong, Jin-Hwa ; Choi, Joong Sub ; Lee, Jung Hun ; Son, Chang Eop ; Jeon, Seung Wook ; Bae, Jong Woon ; Eom, Jeong Min. / Comparison of survival and adverse events between women with stage IB1 and stage IB2 cervical cancer treated by laparoscopic radical vaginal hysterectomy. In: Annals of Surgical Oncology. 2012 ; Vol. 19, No. 2. pp. 605-611.
@article{ba04c003ac9f48cf815d65c49e176907,
title = "Comparison of survival and adverse events between women with stage IB1 and stage IB2 cervical cancer treated by laparoscopic radical vaginal hysterectomy",
abstract = "Purpose: The goal of this study was to evaluate the operative feasibility and survival for patients with stage IB2 cervical cancer who undergo laparoscopic radical vaginal hysterectomy (LRVH) compared with those with stage IB1 cervical cancer. Methods: We identified 90 patients who were eligible to participate in the study through retrospective analysis of medical records from March 2003 to June 2010. Patients with stage IB1 cervical cancer were divided into two groups by a cutoff value of 2 cm for tumor size. Data regarding surgicopathologic risk factors, surgical outcomes, and survival rates were compared among three groups (two with stage IB1 and one with stage IB2). Results: The tumor size was ≤2 cm in 27 patients, 2-4 cm in 30, and >4 cm in 33. The number of intermediate and high-risk factors was significantly lower in patients with stage IB1 cervical cancer (≤2 cm) than in those with stage IB2. Surgical outcomes (mean operating time, estimated blood loss, number of harvested lymph nodes, and sites of metastatic lymph nodes) did not show any significant difference among the three groups. The rates of intraoperative complications also did not differ among the three groups (P = 0.833). The estimated 5-year recurrence-free and overall survival rates were not significantly different among the three groups (P = 0.253 and 0.525, respectively). Conclusions: LRVH for stage IB2 cervical cancer can be performed with similar safety and survival rates compared to stage IB1 cervical cancer. Overall, LRVH is feasible for the treatment of stage IB2 cervical cancer.",
author = "Jin-Hwa Hong and Choi, {Joong Sub} and Lee, {Jung Hun} and Son, {Chang Eop} and Jeon, {Seung Wook} and Bae, {Jong Woon} and Eom, {Jeong Min}",
year = "2012",
month = "2",
day = "1",
doi = "10.1245/s10434-011-1904-z",
language = "English",
volume = "19",
pages = "605--611",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Comparison of survival and adverse events between women with stage IB1 and stage IB2 cervical cancer treated by laparoscopic radical vaginal hysterectomy

AU - Hong, Jin-Hwa

AU - Choi, Joong Sub

AU - Lee, Jung Hun

AU - Son, Chang Eop

AU - Jeon, Seung Wook

AU - Bae, Jong Woon

AU - Eom, Jeong Min

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Purpose: The goal of this study was to evaluate the operative feasibility and survival for patients with stage IB2 cervical cancer who undergo laparoscopic radical vaginal hysterectomy (LRVH) compared with those with stage IB1 cervical cancer. Methods: We identified 90 patients who were eligible to participate in the study through retrospective analysis of medical records from March 2003 to June 2010. Patients with stage IB1 cervical cancer were divided into two groups by a cutoff value of 2 cm for tumor size. Data regarding surgicopathologic risk factors, surgical outcomes, and survival rates were compared among three groups (two with stage IB1 and one with stage IB2). Results: The tumor size was ≤2 cm in 27 patients, 2-4 cm in 30, and >4 cm in 33. The number of intermediate and high-risk factors was significantly lower in patients with stage IB1 cervical cancer (≤2 cm) than in those with stage IB2. Surgical outcomes (mean operating time, estimated blood loss, number of harvested lymph nodes, and sites of metastatic lymph nodes) did not show any significant difference among the three groups. The rates of intraoperative complications also did not differ among the three groups (P = 0.833). The estimated 5-year recurrence-free and overall survival rates were not significantly different among the three groups (P = 0.253 and 0.525, respectively). Conclusions: LRVH for stage IB2 cervical cancer can be performed with similar safety and survival rates compared to stage IB1 cervical cancer. Overall, LRVH is feasible for the treatment of stage IB2 cervical cancer.

AB - Purpose: The goal of this study was to evaluate the operative feasibility and survival for patients with stage IB2 cervical cancer who undergo laparoscopic radical vaginal hysterectomy (LRVH) compared with those with stage IB1 cervical cancer. Methods: We identified 90 patients who were eligible to participate in the study through retrospective analysis of medical records from March 2003 to June 2010. Patients with stage IB1 cervical cancer were divided into two groups by a cutoff value of 2 cm for tumor size. Data regarding surgicopathologic risk factors, surgical outcomes, and survival rates were compared among three groups (two with stage IB1 and one with stage IB2). Results: The tumor size was ≤2 cm in 27 patients, 2-4 cm in 30, and >4 cm in 33. The number of intermediate and high-risk factors was significantly lower in patients with stage IB1 cervical cancer (≤2 cm) than in those with stage IB2. Surgical outcomes (mean operating time, estimated blood loss, number of harvested lymph nodes, and sites of metastatic lymph nodes) did not show any significant difference among the three groups. The rates of intraoperative complications also did not differ among the three groups (P = 0.833). The estimated 5-year recurrence-free and overall survival rates were not significantly different among the three groups (P = 0.253 and 0.525, respectively). Conclusions: LRVH for stage IB2 cervical cancer can be performed with similar safety and survival rates compared to stage IB1 cervical cancer. Overall, LRVH is feasible for the treatment of stage IB2 cervical cancer.

UR - http://www.scopus.com/inward/record.url?scp=84856649713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856649713&partnerID=8YFLogxK

U2 - 10.1245/s10434-011-1904-z

DO - 10.1245/s10434-011-1904-z

M3 - Article

VL - 19

SP - 605

EP - 611

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 2

ER -